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M A J O R A R T I C L E
The Diversity of Meningococcal Carriage Across
the African Meningitis Belt and the Impact of
Vaccination With a Group A Meningococcal
Conjugate Vaccine
The MenAfriCar consortiuma
Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, United Kingdom
Background. Study of meningococcal carriage is essential to understanding the epidemiology of Neisseria
meningitidis infection.
Methods. Twenty cross-sectional carriage surveys were conducted in 7 countries in the African meningitis belt; 5
surveys were conducted after introduction of a new serogroup A meningococcal conjugate vaccine (MenAfriVac).
Pharyngeal swab specimens were collected, and Neisseria species were identiﬁed by microbiological and molecular
techniques.
Results. A total of 1687 of 48 490 participants (3.4%; 95% conﬁdence interval [CI], 3.2%–3.6%) carried menin-
gococci. Carriage was more frequent in individuals aged 5–14 years, relative to those aged 15–29 years (adjusted odds
ratio [OR], 1.41; 95% CI, 1.25–1.60); in males, relative to females (adjusted OR, 1.17; 95% CI, 1.10–1.24); in indi-
viduals in rural areas, relative to those in urban areas (adjusted OR, 1.44; 95% CI, 1.28–1.63); and in the dry season,
relative to the rainy season (adjusted OR, 1.54; 95% CI, 1.37–1.75). Forty-eight percent of isolates had genes encoding
disease-associated polysaccharide capsules; genogroup W predominated, and genogroup A was rare. Strain diversity
was lower in countries in the center of the meningitis belt than in Senegal or Ethiopia. The prevalence of genogroup
A fell from 0.7% to 0.02% in Chad following mass vaccination with MenAfriVac.
Conclusions. The prevalence of meningococcal carriage in the African meningitis belt is lower than in indus-
trialized countries and is very diverse and dynamic, even in the absence of vaccination.
Keywords. Africa; meningitis; meningococcus; Neisseria meningitidis; carriage.
For >100 years, large, seasonal epidemics of meningoco-
ccal meningitis have occurred periodically in the African
meningitis belt [1], causing thousands of cases and
many deaths and severely disrupting health systems [2].
Meningitis and septicemia are rare outcomes of menin-
gococcal infection, and most infections with Neisseria
meningitidis result in asymptomatic pharyngeal car-
riage. Therefore, the underlying transmission dynamics
can be determined accurately only by study of carriage
and disease, a feature of N. meningitidis infection ﬁrst
recognized 70 years ago [3].
In high-income countries, meningococcal carriage
occurs most frequently in older children and young
adults and is linked to smoking, nightclub attendance,
and intimate kissing [4]. Less is known about the epide-
miology and risks factors of meningococcal carriage in
the African meningitis belt. A review of studies under-
taken in the meningitis belt prior to 2007 showed that
the prevalence of meningococcal carriage varied mark-
edly between surveys, as did the distribution of sero-
groups [5]. Some of these differences may have arisen
because surveys were undertaken at different times of the
year and in different age groups and because they used a
variety of swabbing and microbiological techniques.
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Only a few additional African carriage studies have been reported
since the 2007 review, all from Burkina Faso, and these have also
shown considerable heterogeneity [6–10]. In 2009, Kristiansen
et al conducted large, sequential carriage studies in participants
aged 1–29 years in 1 urban and 2 rural communities in Burkina
Faso [9] prior to introduction of a new serogroup A meningo-
coccal polysaccharide/tetanus toxoid conjugate vaccine (PsA-
TT; MenAfriVac). The prevalence of carriage among 20 326
participants was 4.0%, with the highest prevalence among
males aged 15–19 years and females aged 10–14 years.
Because carriage is central to an understanding of the epidemi-
ology of meningococcal infection in the African meningitis belt,
the African Meningococcal Carriage Consortium (MenAfriCar)
was established in 2008 to study the pattern of meningococcal
carriage in this region before and after the introduction of
PsA-TT, using standardized ﬁeld and laboratory methods [11].
Here we report the ﬁndings from 20 age-stratiﬁed, cross-sectional
surveys conducted in 7 countries before and in 3 countries after
the introduction of PsA-TT.
METHODS
The ﬁeld and laboratory methods used in the MenAfriCar sur-
veys have been described in detail previously [11] and are sum-
marized here.
Study Sites and Carriage Surveys
Carriage studies were conducted in 1 urban and 1 rural area in 7
countries in the meningitis belt (Supplementary Figure 1) during
the dry seasons of 2010 and 2011 and during the rainy season of
2012. Following pilot studies [12], 3 cross-sectional surveys were
undertaken in all countries except Nigeria, where only 2 surveys
could be done because of increasing political instability. Prevac-
cination surveys in Mali, Niger, and Chad had a target of 5000
participants, and postvaccination surveys a target of 2000 partic-
ipants in Mali and Niger and 6000 in Chad. The remaining sur-
veys had a target of 2000 participants. A representative sample
framewas obtained either from an updated, ongoing demograph-
ic surveillance system (DSS) or from a census conducted specif-
ically for the study. Multistage sampling was used. Study
households were randomly selected from the DSS or census.
Within selected households, individuals stratiﬁed by age group
(0–4 years, 5–14 years, 15–29 years, and ≥30 years) were chosen
randomly until the required sample size was reached. Following
receipt of written consent, standardized household and individ-
ual questionnaires enquiring about risk factors for meningococ-
cal infection were administered.
Based on an estimated serogroup A meningococcal carriage
rate of 1% in prevaccination surveys, a sample size of 2000 was
estimated to be large enough to enable meaningful comparisons
to be made between countries, site (urban vs rural), season, and
age group. A sample of 5000 was estimated to have 80% power
to show a 50% reduction in serogroup A carriage following
vaccination.
Isolation and Characterization of Meningococci
Swabbing Technique
Pilot studies established that swabbing both the posterior phar-
ynx and the tonsils or just the posterior of the pharynx were
equally effective methods of isolating N. meningitidis [12],
and the former method was used in all subsequent surveys.
Identiﬁcation of N. meningitidis
Pharyngeal swabs were plated directly onto modiﬁed Thayer-
Martin agar plates in the ﬁeld and taken to the laboratory within
6 hours of collection. Details of the conventional bacteriological
techniques used to identify and serogroup meningococci [11]
are provided in the Supplementary Materials. At 6 of 7 African
centers, porA polymerase chain reaction (PCR) was undertaken
to conﬁrm the identity of isolates of N. meningitidis identiﬁed
by routine microbiological analysis, and if this test had positive
results, an A, X, and W multiplex genogrouping PCR was per-
formed. If the result of this ﬁrst multiplex PCR was negative,
singleplex Y genogrouping PCR was performed.
To conﬁrm the identity of Neisseria identiﬁed by culture,
samples of boiled suspensions of oxidase-positive, gram-
negative bacteria were sent to the University of Oxford for
molecular analysis [11, 13], as described in the Supplementary
Materials. Speciation was done by sequencing the ribosomal
protein L6 gene rplF [13], and N. meningitidis isolates were
characterized by sequencing the 2 variable regions of the porA
gene and of the capsule-null (cnl) intergenic region to identify
unencapsulated bacteria. Finally, genogroups were identiﬁed by
using 2 multiplex real-time PCR assays to detect genes encoding
capsules corresponding to the disease-associated serogroups A,
B, C, W, X, and Y (giving the respective genogroup).
Data Management
Data were managed using the Teleform system as described pre-
viously [11]. This allows study forms to be speciﬁcally designed,
scanned after completion, automatically read, and then veriﬁed
before being exported to a database. Local and central databases
were designed to accommodate the study forms, and a separate
database module was developed to automatically populate the
central database with genetic laboratory results from the Neisse-
ria sequence typing database (http://PubMLST.org/Neisseria)
[14, 15]. Records from laboratory reports and questionnaires
were linked using the unique study number assigned to each
individual. Data cleaning was performed using Stata, version
12.0 (StataCorp, College Station, Texas). Any laboratory report
that could not be linked to a questionnaire that contained
information on the age of the participant was excluded. These
exclusions are shown in Supplementary Table 1; only 18 menin-
gococci, 15 of which were from the ﬁrst survey, were excluded.
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Statistical Methods
Analyses were performed using Stata, version 12.0. We account-
ed for potential household clustering, using the survey com-
mands in Stata. Overall and age-stratiﬁed carriage prevalence
rates were calculated, together with 95% conﬁdence intervals
(CIs), for each country and each survey. The Simpson diversity
index was calculated for each country, based on the strains (gen-
ogroup and PorA subtype) isolated across all surveys. Risk fac-
tors for carriage were assessed using logistic regression. Each
risk factor was considered in turn, using univariable logistic re-
gression. A multivariable model was then constructed that in-
cluded country, season, age group, and sex a priori and any
variable with a P value of <.1 in the univariable analyses, with
those with a P value of <.05 in the multivariable analysis re-
tained. As a ﬁnal check, dropped variables were reentered into
the model one at a time, and the P values were reexamined; the
variable was retained if P < .05. A multinomial logistic regres-
sion model was constructed to compare risk factors for carriage
of meningococci with and those without capsular genes.
RESULTS
Participants Surveyed
The number of participants in each survey, the year and season
of the survey, and the relationship of the survey to the introduc-
tion of PsA-TT are shown in Table 1. Most surveys recruited
close to their target number of participants, and there was
even sampling between age groups (Supplementary Table 2).
Participants aged 5–29 years were recruited preferentially for
the postvaccination survey in Chad in 2012 to maximize the
chance of identifying serogroup A meningococcal carriers and
of being able to assess the impact of vaccination.
Prevalence of N. meningitidis Carriage
A total of 1687 meningococci were identiﬁed, for an overall car-
riage prevalence of 3.4% (95% CI, 3.2%–3.6%) after adjustment
for survey design. There was marked variation in the prevalence
of carriage between centers and between surveys within each cen-
ter (Figure 1). The age distribution of carriers by center and sur-
vey was more consistent (Figure 2). Combining the results from
all surveys, the prevalence of carriage by age was 1.8% (95% CI,
1.3%–2.4%) for <1 year, 2.6% (95% CI, 2.2%–2.9%) for 1–4 years,
4.9% (95% CI, 4.5%–5.3%) for 5–14 years, 3.6% (95% CI, 3.2%–
3.9%) for 15–29 years, and 2.6% (95% CI, 2.3%–2.9%) for ≥30
years. The age distribution of carriers by country and survey is
shown in Supplementary Figure 2. The overall prevalence of car-
riage in males (4.1%; 95% CI, 3.8%–4.3%) was higher than in fe-
males (3.0%; 95% CI, 2.7%–3.2%), and this difference was seen in
5 of 7 participating countries. The most marked sex difference in
prevalence was seen in 15–29 year olds, in whom carriage in
males was signiﬁcantly higher than in females (5.1% vs 2.8%;
P < .0001; Figure 3). Generally, the prevalence of carriage was
higher in the dry season (4.2%; 95% CI, 3.8%–4.5%) than in
the rainy season (3.1%; 95% CI, 2.9%–3.3%); this difference
Table 1. Numbers of Subjects Studied, by Country, During Each
Survey
Country
Survey 1, Rainy
Season, July–
December 2010
Survey 2, Rainy
Season, July–
November 2011
Survey 3, Dry
Season, February–
July 2012
Chad 1986 5307 6103a
Ethiopia 1884 2025 2061
Ghana 1159 2031 2019
Mali 4844 1994a 1999a
Niger 4235 1963a 2015a
Nigeria 1520 936 0
Senegal 1414 1680 1315
Overall 17 042 15 936 15 512
a Data are from a postvaccination survey.
Figure 1. Carriage prevalence, by country and survey. Asterisks denote
postvaccination surveys.
Figure 2. Carriage prevalence, by age and survey.
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was observed in 4 of 7 participating countries. The prevalence of
carriage was higher in rural areas (3.6%; 95% CI, 3.3%–3.9%)
than in urban areas (3.2%; 95% CI, 2.9%–3.5%), and this differ-
ence, although not statistically signiﬁcant, was observed in 5 of 7
participating countries (Supplementary Table 3). The most fre-
quently identiﬁed Neisseria species other than N. meningitidis
wasNeisseria lactamica (2588 individuals [5.4%]); otherNeisseria
species were found at a lower prevalence.
Strain Characteristics of N. meningitidis Carriage Isolates
Genes characteristic of disease-associated capsules were detect-
ed in 48% of the 1687 meningococci identiﬁed: genogroup A, 46
isolates (0.09% overall prevalence); genogroup B, 17 isolates
(0.04%); genogroup C, 30 isolates (0.06%); genogroup W, 623
isolates (1.3%); genogroup X, 27 isolates (0.06%); and gen-
ogroup Y, 68 isolates (0.14%). Two genogroups were identiﬁed
in 3 samples: 2 with genogroup A and X, and 1 with genogroup
X and C. The overall prevalence of carriage with cnl meningo-
cocci was 1.6% (778 isolates). Neither a capsular gene nor the
cnl intergenic region was detected in 101 samples identiﬁed mi-
crobiologically as N. meningitidis. It is likely that these were me-
ningococci with capsules not usually associated with disease
and whose capsular genes were not detected [16]. In 169 sam-
ples identiﬁed as meningococci, we found evidence of both a
capsule-null locus and a capsular gene. This suggests that
there was cocolonization with >1 meningococcal strain or per-
haps cocolonization with 2 different Neisseria species, as the cnl
intergenic region is present in all nonmeningococcal Neisseria
species, as well as some meningococci. The distribution of the
different genogroups varied substantially by center and survey
(Figure 4A–C). Although numbers within subgroups were
small, there was no indication that that genogroup was associ-
ated preferentially with a particular age group or sex within the
context of a country or survey (Supplementary Table 4).
A wide diversity of porA subtypes was recorded, with
63 unique combinations identiﬁed among the samples typed
for both VR1 and VR2. However, 3 subtypes accounted for
Figure 4. Distribution of Neisseria meningitidis genogroups, by country
and survey. The overall prevalence of carriage in each country during the
survey is shown in brackets. A, First cross-sectional survey in 2010 (rainy
season). At this time, no country had introduced serogroup A meningococ-
cal conjugate vaccine (MenAfriVac). B, Second cross-sectional survey in
2011 (rainy season). At this time, MenAfriVac had been introduced in
Mali and Niger, as indicated by asterisks. C, Third cross-sectional survey
in 2012 (dry season). At this time, MenAfriVac had been introduced in Mali,
Niger, and Chad, as indicated by asterisks.
Figure 3. Carriage prevalence, by age and sex (all surveys combined).
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Figure 5. Distribution of strain types across the meningitis belt. The number of meningococci isolated in each country is indicated. A, Survey 1 (2010). At
this time, no country had introduced serogroup A meningococcal conjugate vaccine (MenAfriVac). B, Survey 2 (2011). At this time, MenAfriVac had been
introduced in Mali and Niger, as indicated by asterisks. C, Survey 3 (2012). At this time, MenAfriVac had been introduced in Mali, Niger, and Chad, as
indicated by asterisks.
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68.8% of all the meningococci isolated. The most frequently de-
tected subtype was P1.18-11,42-1 (n = 547), which was usually
associated with the presence of the cnl intergenic region (93%).
The next most common subtype was P1.5,2 (n = 493), which
was strongly associated with genogroup W (97%), followed by
P1.5-1,2–36 (n = 121), which was also associated strongly with
genogroup W (89%). Forty-one of the 46 genogroup A menin-
gococci were subtyped as P1.20,9.
The combination of genogroup and PorA subtype provides a
strain designation; 132 distinct strains were identiﬁed. The most
frequently identiﬁed strain type was NG(cnl):P1.18-11,42-1
(n = 511), followed by W:P1.5,2 (n = 479) and W:P1.5-1,2-36
(n = 108). All other strain types were isolated on <50 occasions.
The strain distribution by country and by survey is illustrated in
Figure 5. More strain diversity was observed in Ethiopia and
Senegal, countries at the eastern and western edges of the men-
ingitis belt, than in countries situated in the central part of the
belt. The Simpson diversity index (from most to least diverse)
was estimated to be 0.021 in Ethiopia, 0.031 in Senegal, 0.035 in
Niger, 0.051 in Ghana, 0.052 in Chad, and 0.073 in Mali. Me-
ningococci isolated in Ethiopia were >3 times as diverse as those
from Mali.
Risk Factors for N. meningitidis Carriage
Risk factors for carriage with N. meningitidis at the individual
level are shown in Table 2. Age, sex, season, rural site, crowding
(≥2 people per room), smoking in the household, and indoor
kitchen facilities remained statistically signiﬁcant risk factors
in a multivariable logistic regression analysis. Recent immuni-
zation (within 1 year) with a meningitis vaccine (self-reported)
was associated with a lower odds of carriage of capsulated me-
ningococci, after accounting for other factors. Respiratory
symptoms and a history of attending social gatherings in the
past week were associated with a lower odds of carriage in uni-
variable analysis, but both variables dropped out in multivari-
able analysis. Risk factors for carriage of genogroupable and
capsule-null meningococci are shown in Supplementary Table 5.
Dry season and the location of the kitchen were associated sig-
niﬁcantly with a higher odds of carriage of genogroupable but
not cnl meningococci.
Impact of Vaccination
Surveys were conducted before and after vaccination with PsA-
TT in 3 countries (Chad, Mali, and Niger). In Chad, where an
epidemic of serogroup A meningococcal disease was occurring
at the time of vaccination, a marked drop in the prevalence of
genogroup A meningococcal carriage was observed 4–6 months
following vaccination (from 0.7% to 0.02%; P < .0001), as re-
ported previously [17]. In Chad, PorA characterization of me-
ningococcal isolates before and after vaccination showed a
marked change in pattern, with a substantial reduction in the
prevalence of the PorA subtype P1.20.9 associated with
genogroup A (P < .0001), and a marked increase in both the
proportion and overall prevalence of the cnl-associated subtype
P1.18,42-1 (Figure 5). However, similar rapid changes in strain
prevalence over time occurred in other countries where vac-
cination was not introduced during the period of the surveys,
including Ethiopia and Senegal. In Mali and Niger, no gen-
ogroup A meningococcal carriers were identiﬁed during the
survey conducted 4–6 months before vaccination with PsA-
TT, so the impact of vaccination on genogroup A carriage
could not be assessed.
DISCUSSION
Results from 20 standardized surveys conducted by the MenA-
friCar consortium in 7 countries across the African meningitis
belt at approximately the same time conﬁrm the ﬁndings of pre-
vious studies undertaken at single sites, at different times of the
year, and with different techniques that meningococcal carriage
in the African meningitis belt is both complex and highly dy-
namic, both in terms of the prevalence of carriage and menin-
gococcal genogroup [5, 18]. This is illustrated well by the
ﬁndings from Senegal, where carriage prevalence increased
from around 3% in the ﬁrst and second surveys to 19.8% in
the third survey with the emergence of a strain type not ob-
served in the previous surveys.
The overall prevalence of meningococcal carriage (3.4%) de-
tected during the 20 surveys was substantially lower than that
recorded in most population surveys undertaken in high-
income countries with a temperate climate, where carriage prev-
alences 2 or 3 times greater are usually recorded [19]. Similar
ﬁndings to ours were obtained recently in Burkina Faso,
where surveys conducted before and after the introduction of
PsA-TT showed the overall meningococcal carriage rate to be
low (4% in prevaccine studies and 7% in postvaccine studies)
[14]. In addition to the low prevalence of carriage found during
the MenAfriCar surveys, the diversity of strain types was more
restricted in the central part of the meningitis belt than would
be expected in high-income countries with a temperate climate.
The distribution of strain types in Butajira, Ethiopia, which does
not have a climate typical of the Sahel, was more diverse and
closer to that found in countries with a temperate climate
than in countries at the center of the meningitis belt. Detection
of a low prevalence of carriage and low strain diversity in coun-
tries of the meningitis belt seems, at ﬁrst, to be counterintuitive
but is consistent with the general theory that infectious diseases
epidemics occur in situations where an infection is uncommon
and population susceptibility is high.
The proportion of nongroupable, capsule-null N. meningiti-
dis found in nearly all surveys was higher than that found in
comparable studies conducted in high-income countries with
a temperate climate [20, 21]. The reason and signiﬁcance of
this phenomenon is uncertain, but it warrants further
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Table 2. Univariable and Multivariable Logistic Regression Analysis of Factors Associated With Neisseria meningitidis Carriage
Factor
Subjects, No.
(Carriers, No.)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
Age, y
<1 2199 (41) 0.50 (.37–.69) 0.37 (.27–.51)
1–4 8839 (228) 0.72 (.61–.84) 0.59 (.50–.69)
5–14 13 121 (655) 1.41 (1.35–1.58) 1.41 (1.25–1.60)
15–29 12 426 (450) 1.0 1.0
≥30 11 905 (313) 0.72 (.62–.83) 0.60 (.51–.69)
Sexa
Female 27 981 (835) 1.0 1.0
Male 20 353 (825) 1.37 (1.25–1.51) 1.17 (1.10–1.24)
Season
Rainy (XS1 and XS2) 32 978 (1039) 1.0 1.0
Dry (XS3) 15 512 (648) 1.31 (1.21–1.53) 1.54 (1.37–1.75)
Country
Chad 13 396 (131) 1.0 1.0
Ethiopia 5970 (389) 7.12 (5.71–8.89) 7.04 (5.39–9.21)
Ghana 5209 (193) 4.03 (3.15–5.15) 4.76 (3.62–6.29)
Mali 8837 (79) 0.95 (.71–1.27) 1.42 (1.03–195)
Niger 8213 (535) 7.27 (5.93–8.93) 10.16 (8.03–12.84)
Nigeria 2456 (3) 0.09 (.02–.35) 0.11 (.03–.45)
Senegal 4409 (357) 9.23 (7.40–11.50) 9.58(7.30–12.58)
Area
Urban 20 218 (644) 1.0 1.0
Rural 28 205 (1017) 1.14 (1.01–1.28) 1.44 (1.28–1.63)
Crowdingb
<2 people per room 16 908 (460) 1.0 1.0
≥2 people per room 31 515 (1201) 1.42 (1.25–1.61) 1.24 (1.09–1.42)
Smoking statusc
Nonsmoker 22 312 (705) 1.0 . . .
Smoker 1231 (43) 1.11 (.81–1.51) . . .
Smokers in household
No 35 523 (1164) 1.0 1.0
Yes 12 881 (497) 1.18 (1.04–1.34) 1.16 (1.02–1.33)
Cooking fuel
Oil based 533 (7) 0.46 (.22–.97) . . .
Wood based 41 825 (1172 1.0 . . .
Cow dung/straw 5729 (472) 3.11 (2.73–3.55) . . .
Kitchen location
Open air 18 934 (512) 1.0 1.0
Inside house 13 322 (824) 2.37 (2.09–2.70) 1.35 (1.12–1.63)
Separate hut 15 268 (304) 0.72 (.61–.84) 0.95 (.77–1.18)
Missing information 595 (21) 1.32 (.73–2.38) 1.11 (.60–2.07)
Vaccinated recently with meningitis vaccine
No 33 598 (1230) 1.0 1.0
Yes, <1 y ago 9132 (227) 0.67 (.57–.78) 0.72 (.60–.85)
Yes, 1–3 y ago 4589 (171) 1.01 (.85–1.21) 0.52 (.42–.63)
Don’t know/ missing 1171 (59) 0.81 (.56–1.16) 1.09 (.50–1.04)
Respiratory symptoms
No 26 555 (1077) 1.0 . . .
Yes 21 935 (610) 0.69 (.62–.77) . . .
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investigation because the presence of these strains could inﬂu-
ence infections with capsulated meningococci.
The prevalence of meningococcal carriage by age was consis-
tent with most previous surveys conducted in Africa, with the
highest value detected in individuals aged 5–14 years [5]. This
age pattern is compatible with substantial transmission occurring
outside households between school-aged children. Risk factors for
carriage were similar to those reported previously in Africa [22]
but different from those seen in other settings where carriage
peaks in young adults [19]. Carriage was more prevalent in
males than females, perhaps because of more-frequent social mix-
ing among young adult males than females inMuslim societies; in
rural areas than urban areas; and in those exposed to smoke, ei-
ther from cigarettes or from cooking. Development of less pollut-
ing methods of cooking is a priority for many parts of the
developing world [23] and could contribute to a reduction in
the incidence of meningococcal infection, as well as the incidence
of pneumonia. The absence of an association between carriage
and recent respiratory symptoms contrasts with ﬁndings from
studies in Burkina Faso [6]. The lack of any association with at-
tendance at social gatherings was inconsistent with ﬁndings from
the United Kingdom, where social behavior was closely linked to
the risk of carriage [4].However, in the present study, information
on the number and types of gatherings attended but not the fre-
quency of attendance was collected. Previous vaccination (within
3 years) was associated with a lower risk of carriage of capsulated
meningococci. Since this ﬁnding relates mainly to the use of poly-
saccharide vaccines in Ghana (A+C polysaccharide vaccine) and
Senegal (A+C+W polysaccharide vaccine) rather than the use of
MenAfriVac, and because polysaccharide vaccines have little
effect on carriage [24], this association is most likely due to
unmeasured confounding. The odds of carriage with meningo-
cocci that possessed a capsular gene was higher in the dry season
than in the rainy season, whereas there was no signiﬁcant differ-
ence in the odds of carriage for unencapsulated (cnl) strains by
season. An indoor kitchen was an additional risk factor for gen-
ogroupable meningococci, compared with capsule-null strains.
These ﬁndings are consistent with the idea that the capsule
protects meningococci against desiccation during aerosol trans-
mission [25].
The MenAfriCar surveys were timed to permit the impact of
the PsA-TT vaccine to be evaluated in Chad, Mali, and Niger.
However, in Mali and Niger, carriers of group A meningococci
were not found in prevaccination surveys, so it was not possible
to measure the impact of vaccination on group A carriage in
these countries. It seems unlikely that PsA-TT would have
had any impact on other serogroups in Mali or Niger (se-
rogroup replacement), because there were no serogroup A me-
ningococci present prior to vaccination to displace. In Niger,
where the recent epidemiology of meningococcal disease has
been studied in detail [26], the decline in group A infections ap-
pears to have been part of a natural cycle, rather than due to
vaccination. In Chad, where an epidemic of group A meningo-
coccal disease was in progress at the time that PsA-TT was
introduced in part of the country, vaccination was associated
with a dramatic reduction in the prevalence of carriage of gen-
ogroup A meningococci in both vaccinated and unvaccinated
participants, as reported previously [17] and as observed also
in Burkina Faso [14]. However, because only data before and
after vaccine introduction were obtained in both studies, and
because rapid changes in carriage may occur independently
of vaccination, these ﬁndings need to be considered with
caution. Assessment of carriage dynamics beyond 1 year is
needed to evaluate the long-term impact of PsA-TT in the
meningitis belt.
An important part of the MenAfriCar project was capacity
building through strengthening the ability of our study centers
to undertake meningococcal carriage surveys and disease sur-
veillance. Standardization of methods was undertaken through
workshops and site visits. The Institut Pasteur (Paris, France)
conducted quality-control studies for the consortium. Never-
theless, it is still possible that some of the variability in preva-
lence of carriage seen between centers and surveys was due to
technical differences rather than to biological factors, but use
of conﬁrmatory molecular characterization of DNA samples
has reduced this risk.
Table 2 continued.
Factor
Subjects, No.
(Carriers, No.)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
Social gatherings
None attended 20 370 (872) 1.0 . . .
1–2 types of gathering attended 24 719 (702) 0.65 (.59–.72) . . .
≥3 types of gathering attended 3333 (87) 0.60 (.48–.75) . . .
The final multivariable logistic regression model included age group, sex, country, survey, area, crowding, household smokers, recent vaccination and kitchen location.
Abbreviations: CI, confidence interval; OR, odds ratio.
a Data were not reported for 135 individuals.
b Data were missing for 67 individuals.
c Only adults were asked about their smoking habits.
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It is likely that widespread deployment of PsA-TT, now given
to >217 million people in countries of the meningitis belt, will
prevent future epidemics of serogroup A meningococcal men-
ingitis, at least for a number of years. However, meningococci of
other serogroups (C, W, and X) have the potential to cause
epidemics [27], and it is uncertain what impact elimination of
serogroup A meningococci will have on the frequency of out-
breaks caused by these serogroups. Whether or not mass vacci-
nation drives serogroup replacement is likely to be determined
in part by the complex interactions within the bacterial ecology
of the pharynx, a subject that deserves further study.
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and University of Oxford, United Kingdom: Julia Bennett,
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Rebbetts, and Eleanor Watkins.
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